OnKure Therapeutics, Inc. Class A Common Stock (OKUR) Stock
Key stats
- Market cap
- $138.40M
- Price / Earnings ratio
- -2.2x
- EPS (TTM)
- -$2.77
- Volume
- Loading
- 52-week high
- $5.38
- 52-week low
- $2.01
Source: third-party data provider, as of November 13, 2026
Compare with OKUR
Technical indicators
- RSI 14
- 70.99
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.00
- MACD histogram
- 0.12
- SMA 50
- $2.76
- Price above SMA 50
- EMA 50
- $2.88
- Price above EMA 50
- SMA 200
- $3.61
- Price below SMA 200
- EMA 200
- $3.29
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About OnKure Therapeutics, Inc. Class A Common Stock
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Nicholas A. Saccomano Ph.D. | President, CEO & Director | 1959 |
| Mr. Jason A. Leverone CPA | Chief Financial Officer | 1974 |
| Dr. Isaac Manke Ph.D. | Senior VP of Business Development & Director | 1977 |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer | 1973 |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary | — |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery | — |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology | — |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry | — |
| Ms. Roberta Alton | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 70.99
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.00
- MACD histogram
- 0.12
- SMA 50
- $2.76
- Price above SMA 50
- EMA 50
- $2.88
- Price above EMA 50
- SMA 200
- $3.61
- Price below SMA 200
- EMA 200
- $3.29
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $14.00
- High
- $14.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.6 | -14.3 | -9.7 | -23.3 | +3.1 | +29.7 |




